We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Should You Continue to Hold Thermo Fisher Stock in Your Portfolio Now?
Read MoreHide Full Article
Key Takeaways
Thermo Fisher completed Solventum's Purification & Filtration deal and bought Olink to expand proteomics.
TMO's steady R&D is fueling launches from Orbitrap mass spectrometers to the Krios 5 Cryo-TEM.
Thermo Fisher faces high leverage and currency pressure, with Q1 2025 FX cutting revenues by 1%.
Thermo Fisher Scientific Inc.’s (TMO - Free Report) recent slew of strategic collaborations reflects its ongoing commitment to sustainable long-term growth. Additionally, the slew of product launches is expected to bolster the company’s top line. Meanwhile, a weak solvency and fierce competitive pressure raise concerns for Thermo Fisher’s operations.
In the past year, this Zacks Rank #3 (Hold) stock has gained 9% compared with the industry’s 3.4% growth. The S&P 500 composite has gained 22.2% in the said period.
The renowned medical and laboratory equipment provider has a market capitalization of $231.23 billion. TMO has an earnings yield of 4% compared with the industry’s 0.6%. The company’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 3%.
Let’s delve deeper.
Upsides for TMO Stock
Strategic Acquisitions to Boost Growth: Thermo Fisher’s business strategy primarily includes expansion through strategic acquisition of technologies and businesses that augment its existing products and services. In September 2025, the company completed the $4.1 billion acquisition of Solventum’s Purification & Filtration business, now part of the Life Sciences Solutions segment. Last year, Thermo Fisher acquired Olink, a Swedish-based provider of next-generation proteomics solutions. The buyout advanced Thermo Fisher’s capabilities in the high-growth proteomics market by adding highly differentiated solutions.
Product Launch Impressive: Thermo Fisher continues to make significant investments in research and development (R&D) to deliver a steady flow of innovative products and strengthen its competitive position. The company introduced the Thermo Scientific Hypulse Surface Analysis System to accelerate the understanding of material surfaces. Thermo Fisher expanded the Efficient-Pro medium and feed system with Efficient-Pro Medium (+) Insulin, supporting optimized growth and productivity for insulin-dependent CHO cell lines with streamlined workflow and handling.
Other important launches this year include two next-generation Thermo Scientific Orbitrap mass spectrometers, the Invitrogen Attune Xenith Flow Cytometer and the Thermo Scientific Krios 5 Cryo-Transmission Electron Microscope (TEM).
Concerns for TMO
Unfavorable Solvency: As of the end of the third quarter of 2025, Thermo Fisher reported cash and cash equivalents and short-term investments of $3.55 billion and current debt of $3.82 billion. Long-term debt totaled $31.86 billion. The company reported a leverage ratio of 3.2 times gross debt to adjusted EBITDA and 2.9 times on a net debt basis.
Image Source: Zacks Investment Research
Exposure to Foreign Currency: International markets account for a substantial portion of Thermo Fisher’s revenues and the company intends to continue expanding its presence in these regions. International revenues and costs are subject to foreign exchange risk, as fluctuations in currency exchange rates may adversely impact reported revenues and profitability when translated into U.S. dollars for financial reporting purposes. For instance, in the first quarter of 2025, currency translation had an unfavorable effect of 1% on revenues due to the strengthening of the U.S. dollar relative to other currencies in which the company sells its products and services.
TMO Stock Estimate Trend
The Zacks Consensus Estimate for earnings per share (EPS) has moved up 1 cent to $22.73 in the past 30 days.
The Zacks Consensus Estimate for the company’s 2025 revenues is pegged at $44.27 billion, suggesting a 3.2% rise from the year-ago reported number.
Phibro Animal Health has an earnings yield of 7.4% compared with the industry’s 0.2% yield. Shares of the company have surged 86.2% in the past year against the industry’s 5% decline. PAHC’s earnings outpaced estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 20.8%.
Boston Scientific, currently carrying a Zacks Rank #2 (Buy), has an estimated long-term earnings growth rate of 16.4% compared with the industry’s 13.9% growth. Its earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with the average surprise being 7.36%. BSX shares have surged 130.2% compared with the industry’s 5.2% growth in the past year.
Envista, carrying a Zacks Rank #2 at present, has an earnings yield of 5.4% compared with the industry’s 2.8% yield. Shares of the company have jumped 13.9% compared with the industry’s 5.2% growth. NVST’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 12.8%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Should You Continue to Hold Thermo Fisher Stock in Your Portfolio Now?
Key Takeaways
Thermo Fisher Scientific Inc.’s (TMO - Free Report) recent slew of strategic collaborations reflects its ongoing commitment to sustainable long-term growth. Additionally, the slew of product launches is expected to bolster the company’s top line. Meanwhile, a weak solvency and fierce competitive pressure raise concerns for Thermo Fisher’s operations.
In the past year, this Zacks Rank #3 (Hold) stock has gained 9% compared with the industry’s 3.4% growth. The S&P 500 composite has gained 22.2% in the said period.
The renowned medical and laboratory equipment provider has a market capitalization of $231.23 billion. TMO has an earnings yield of 4% compared with the industry’s 0.6%. The company’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 3%.
Let’s delve deeper.
Upsides for TMO Stock
Strategic Acquisitions to Boost Growth: Thermo Fisher’s business strategy primarily includes expansion through strategic acquisition of technologies and businesses that augment its existing products and services. In September 2025, the company completed the $4.1 billion acquisition of Solventum’s Purification & Filtration business, now part of the Life Sciences Solutions segment. Last year, Thermo Fisher acquired Olink, a Swedish-based provider of next-generation proteomics solutions. The buyout advanced Thermo Fisher’s capabilities in the high-growth proteomics market by adding highly differentiated solutions.
Product Launch Impressive: Thermo Fisher continues to make significant investments in research and development (R&D) to deliver a steady flow of innovative products and strengthen its competitive position. The company introduced the Thermo Scientific Hypulse Surface Analysis System to accelerate the understanding of material surfaces. Thermo Fisher expanded the Efficient-Pro medium and feed system with Efficient-Pro Medium (+) Insulin, supporting optimized growth and productivity for insulin-dependent CHO cell lines with streamlined workflow and handling.
Other important launches this year include two next-generation Thermo Scientific Orbitrap mass spectrometers, the Invitrogen Attune Xenith Flow Cytometer and the Thermo Scientific Krios 5 Cryo-Transmission Electron Microscope (TEM).
Concerns for TMO
Unfavorable Solvency: As of the end of the third quarter of 2025, Thermo Fisher reported cash and cash equivalents and short-term investments of $3.55 billion and current debt of $3.82 billion. Long-term debt totaled $31.86 billion. The company reported a leverage ratio of 3.2 times gross debt to adjusted EBITDA and 2.9 times on a net debt basis.
Image Source: Zacks Investment Research
Exposure to Foreign Currency: International markets account for a substantial portion of Thermo Fisher’s revenues and the company intends to continue expanding its presence in these regions. International revenues and costs are subject to foreign exchange risk, as fluctuations in currency exchange rates may adversely impact reported revenues and profitability when translated into U.S. dollars for financial reporting purposes. For instance, in the first quarter of 2025, currency translation had an unfavorable effect of 1% on revenues due to the strengthening of the U.S. dollar relative to other currencies in which the company sells its products and services.
TMO Stock Estimate Trend
The Zacks Consensus Estimate for earnings per share (EPS) has moved up 1 cent to $22.73 in the past 30 days.
The Zacks Consensus Estimate for the company’s 2025 revenues is pegged at $44.27 billion, suggesting a 3.2% rise from the year-ago reported number.
Key Picks
Some better-ranked stocks in the broader medical space are Phibro Animal Health (PAHC - Free Report) , Boston Scientific (BSX - Free Report) and Envista (NVST - Free Report) .
Phibro Animal Health has an earnings yield of 7.4% compared with the industry’s 0.2% yield. Shares of the company have surged 86.2% in the past year against the industry’s 5% decline. PAHC’s earnings outpaced estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 20.8%.
PAHC sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Boston Scientific, currently carrying a Zacks Rank #2 (Buy), has an estimated long-term earnings growth rate of 16.4% compared with the industry’s 13.9% growth. Its earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with the average surprise being 7.36%. BSX shares have surged 130.2% compared with the industry’s 5.2% growth in the past year.
Envista, carrying a Zacks Rank #2 at present, has an earnings yield of 5.4% compared with the industry’s 2.8% yield. Shares of the company have jumped 13.9% compared with the industry’s 5.2% growth. NVST’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 12.8%.